Clinical, Demographic and Psychosocial Correlates of Complementary and Alternative Medicine Use by Men Diagnosed With Localized Prostate Cancer

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Jul 2003Clinical, Demographic and Psychosocial Correlates of Complementary and Alternative Medicine Use by Men Diagnosed With Localized Prostate Cancer MICHAEL A. DIEFENBACH, NATALIE HAMRICK, ROBERT UZZO, ALAN POLLACK, ERIC HORWITZ, RICHARD GREENBERG, and PAUL F. ENGSTROM MICHAEL A. DIEFENBACHMICHAEL A. DIEFENBACH More articles by this author , NATALIE HAMRICKNATALIE HAMRICK More articles by this author , ROBERT UZZOROBERT UZZO More articles by this author , ALAN POLLACKALAN POLLACK Financial interest and/or other relationship with Amgen, TAP Pharm, Astra Zeneca, Varian, Siemens, Nomos and Calypso. More articles by this author , ERIC HORWITZERIC HORWITZ More articles by this author , RICHARD GREENBERGRICHARD GREENBERG More articles by this author , and PAUL F. ENGSTROMPAUL F. ENGSTROM More articles by this author View All Author Informationhttps://doi.org/10.1097/01.ju.0000070963.12496.ccAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We examined complementary and alternative medicine (CAM) use among men who received standard therapy for localized prostate cancer. Materials and Methods: A total of 417 men completed a questionnaire 6 months after their treatment decision assessing clinical and psychosocial variables and use of 41 available CAM therapies grouped into the 2 general categories of herbal/dietary and nonherbal (ie mind-body, bioelectromagnetic, traditional/folk medicine, pharmacological/biological). Results: The prostate cancer diagnosis prompted 19% of our sample to start using some form of CAM for prostate health, and 67% of men reported having used some form of CAM for prostate health before being diagnosed. Initiation of CAM was associated with being a member of an ethnic minority group and a higher level of education. Initiation of nonherbal CAM was associated with being married, while use of herbal CAM therapies was significantly associated with choosing observation. Herbal use before diagnosis was associated with being white, higher level of education and being single. Prostate specific antigen at diagnosis, Gleason score, quality of life, participant perceptions of seriousness of prostate cancer or self-reported worry about prostate cancer were not related to initiation or prior use. Of those men reporting current use almost 50% did not inform their treating physician of using CAM therapies. Conclusions: Initiation of CAM therapies as a result of a prostate cancer diagnosis was fairly low, although two-thirds of men had used it before diagnosis. Half of the patients did not inform their physicians about such use and physicians should continue to probe patients about CAM use. References 1 : Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA1998; 280: 1569. Crossref, Medline, Google Scholar 2 : Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. Nutr Cancer2001; 39: 12. Google Scholar 3 : SELECT: the next prostate cancer prevention trial. J Urol2001; 166: 1311. Link, Google Scholar 4 : Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer2000; 88: 615. Crossref, Medline, Google Scholar 5 : Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer1999; 86: 2642. Crossref, Medline, Google Scholar 6 : Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol1999; 161: 1521. Link, Google Scholar 7 : C-SHIP: a cognitive-social health information processing approach to cancer. In: Perspectives in Behavioral Medicine. Edited by . New Jersey: Lawrence Erlbaum1998: 219. Google Scholar 8 : Illness cognition: using common sense to understand treatment adherence and affect cognition interactions. Cognit Ther Res1992; 16: 143. Google Scholar 9 : Update of the NCCN guidelines for treatment of prostate cancer. Oncology1997; 11: 180. Medline, Google Scholar 10 : Decision-making strategies for patients with localized prostate cancer. Semin Urol Oncol2002; 20: 55. Google Scholar 11 : Specific worry about breast cancer predicts mammography use in women at risk for breast and ovarian cancer. Health Psychol1999; 18: 532. Google Scholar 12 : Measurement of affective states in adults. Evaluation of an adjective rating scale instrument. Res Aging1989; 11: 403. Google Scholar 13 : Measuring the quality of life in men with prostate cancer using the functional assessment of cancer therapy-prostate instrument. Urology1997; 50: 920. Google Scholar 14 : The use of complementary therapies among breast and prostate cancer patients in Finland. Eur J Cancer Care2002; 11: 44. Google Scholar 15 : Use of alternative medicine by women with early-stage breast cancer. N Engl J Med1999; 340: 1733. Crossref, Medline, Google Scholar 16 : Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst2000; 92: 42. Google Scholar 17 : Prevalence of complementary therapy use by women with breast cancer. A population-based survey. Eur J Cancer2000; 36: 1359. Google Scholar 18 : The use of complementary therapies by breast cancer patients attending conventional treatment. Eur J Cancer1998; 34: 324. Google Scholar From the Division of Population Science, Fox Chase Cancer Center, Cheltenham, Pennsylvania© 2003 by American Urological Association, Inc.FiguresReferencesRelatedDetails Volume 170Issue 1July 2003Page: 166-169 Advertisement Copyright & Permissions© 2003 by American Urological Association, Inc.Keywordsradiotherapyprostatic neoplasms, complementary therapies, surgeryMetricsAuthor Information MICHAEL A. DIEFENBACH More articles by this author NATALIE HAMRICK More articles by this author ROBERT UZZO More articles by this author ALAN POLLACK Financial interest and/or other relationship with Amgen, TAP Pharm, Astra Zeneca, Varian, Siemens, Nomos and Calypso. More articles by this author ERIC HORWITZ More articles by this author RICHARD GREENBERG More articles by this author PAUL F. ENGSTROM More articles by this author Expand All Advertisement PDF downloadLoading ...